Key result
This review summarizes recent studies on the clinical impact of acute rejection after heart transplantation, maintenance immunosuppression regimens, and specific therapeutic options.
Answers are grounded in this paper and cite their sources.
This review discusses the clinical impact, diagnostic grading via endomyocardial biopsy, and immunosuppressive management of acute rejection in heart transplant recipients.
Acute rejection (AR) seems to be less common with current immunosuppressive strategies; however, it remains a major cause of morbidity and mortality in the first year following heart transplantation. Despite great interest in noninvasive methods for detecting rejection, the endomyocardial biopsy remains the standard method for AR identification and, recently, the cardiac biopsy grading system has been reviewed. Moreover, the availability of several immunosuppressive drug combinations has generated confusion in the minds of clinicians. This review will focus on recently published studies that are related to the clinical impact of AR, combination regimens of chronic maintenance immunosuppression and specific therapeutic options for treating AR.
No takes yet. Share an insight, caveat, or question.
Delgado et al. (2006) conducted a review in Acute rejection after heart transplantation. Immunosuppressive strategies and therapeutic options was evaluated. This review summarizes recent studies on the clinical impact of acute rejection after heart transplantation, maintenance immunosuppression regimens, and specific therapeutic options.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: